Throughout the current three months, 6 analysts have shared their insights on Ionis Prescription drugs IONS, expressing a wide range of opinions spanning from bullish to bearish.
The desk under gives a concise overview of current scores by analysts, providing insights into the altering sentiments over the previous 30 days and drawing comparisons with the previous months for a holistic perspective.
| Bullish | Considerably Bullish | Detached | Considerably Bearish | Bearish | |
|---|---|---|---|---|---|
| Whole Rankings | 3 | 2 | 1 | 0 | 0 |
| Final 30D | 2 | 1 | 1 | 0 | 0 |
| 1M In the past | 0 | 0 | 0 | 0 | 0 |
| 2M In the past | 0 | 1 | 0 | 0 | 0 |
| 3M In the past | 1 | 0 | 0 | 0 | 0 |
Insights from analysts’ 12-month worth targets are revealed, presenting a mean goal of $61.5, a excessive estimate of $70.00, and a low estimate of $45.00. This present common represents a 4.65% lower from the earlier common worth goal of $64.50.
Understanding Analyst Rankings: A Complete Breakdown
The standing of Ionis Prescription drugs amongst monetary specialists turns into clear with a radical evaluation of current analyst actions. The abstract under outlines key analysts, their current evaluations, and changes to scores and worth targets.
| Analyst | Analyst Agency | Motion Taken | Score | Present Value Goal | Prior Value Goal |
|---|---|---|---|---|---|
| David Lebowitz | Citigroup | Lowers | Purchase | $64.00 | $67.00 |
| Luca Issi | RBC Capital | Maintains | Outperform | $70.00 | $70.00 |
| Kostas Biliouris | BMO Capital | Lowers | Market Carry out | $45.00 | $60.00 |
| Joseph Stringer | Needham | Maintains | Purchase | $60.00 | $60.00 |
| Luca Issi | RBC Capital | Maintains | Outperform | $70.00 | $70.00 |
| Joseph Stringer | Needham | Maintains | Purchase | $60.00 | $60.00 |
Key Insights:
- Motion Taken: Analysts adapt their suggestions to altering market circumstances and firm efficiency. Whether or not they ‘Keep’, ‘Elevate’ or ‘Decrease’ their stance, it displays their response to current developments associated to Ionis Prescription drugs. This info gives a snapshot of how analysts understand the present state of the corporate.
- Score: Providing insights into predictions, analysts assign qualitative values, from ‘Outperform’ to ‘Underperform’. These scores convey expectations for the relative efficiency of Ionis Prescription drugs in comparison with the broader market.
- Value Targets: Delving into actions, analysts present estimates for the longer term worth of Ionis Prescription drugs’s inventory. This evaluation reveals shifts in analysts’ expectations over time.
Navigating by means of these analyst evaluations alongside different monetary indicators can contribute to a holistic understanding of Ionis Prescription drugs’s market standing. Keep knowledgeable and make data-driven choices with our Rankings Desk.
Keep updated on Ionis Prescription drugs analyst scores.
Discovering Ionis Prescription drugs: A Nearer Look
Ionis Prescription drugs is the main developer of antisense know-how to find and develop novel medicine. Its broad medical and preclinical pipeline targets all kinds of illnesses, with an emphasis on cardiovascular, metabolic, neurological, and uncommon illnesses. Ionis and companion Biogen introduced Spinraza to market in 2016 as a remedy for a uncommon neuromuscular dysfunction, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis introduced two extra medicine to market through its cardiovascular-focused subsidiary Akcea, together with ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
Monetary Milestones: Ionis Prescription drugs’s Journey
Market Capitalization Evaluation: The corporate displays a decrease market capitalization profile, positioning itself under trade averages. This implies a smaller scale relative to friends.
Income Development: Ionis Prescription drugs’s income progress over a interval of three months has confronted challenges. As of 30 September, 2024, the corporate skilled a income decline of roughly -7.21%. This means a lower within the firm’s top-line earnings. When in comparison with others within the Well being Care sector, the corporate faces challenges, reaching a progress price decrease than the common amongst friends.
Web Margin: Ionis Prescription drugs’s monetary energy is mirrored in its distinctive internet margin, which exceeds trade averages. With a exceptional internet margin of -104.98%, the corporate showcases sturdy profitability and efficient price administration.
Return on Fairness (ROE): Ionis Prescription drugs’s ROE lags behind trade averages, suggesting challenges in maximizing returns on fairness capital. With an ROE of -30.34%, the corporate could face hurdles in reaching optimum monetary efficiency.
Return on Belongings (ROA): Ionis Prescription drugs’s ROA lags behind trade averages, suggesting challenges in maximizing returns from its property. With an ROA of -4.87%, the corporate could face hurdles in reaching optimum monetary efficiency.
Debt Administration: The corporate faces challenges in debt administration with a debt-to-equity ratio increased than the trade common. With a ratio of 2.18, warning is suggested because of elevated monetary threat.
Analyst Rankings: What Are They?
Benzinga tracks 150 analyst corporations and stories on their inventory expectations. Analysts sometimes arrive at their conclusions by predicting how a lot cash an organization will make sooner or later, normally the upcoming 5 years, and the way dangerous or predictable that firm’s income streams are.
Analysts attend firm convention calls and conferences, analysis firm monetary statements, and talk with insiders to publish their scores on shares. Analysts sometimes price every inventory as soon as per quarter or every time the corporate has a significant replace.
Past their customary evaluations, some analysts contribute predictions for metrics like progress estimates, earnings, and income, furnishing traders with extra steerage. Customers of analyst scores must be conscious that this specialised recommendation is formed by human views and could also be topic to variability.
Breaking: Wall Avenue’s Subsequent Massive Mover
Benzinga’s #1 analyst simply recognized a inventory poised for explosive progress. This under-the-radar firm may surge 200%+ as main market shifts unfold. Click on right here for pressing particulars.
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
